Johnson & Johnson (Pty) Ltd’s $13.1bn acquisition of Shockwave Medical will greatly expand the medtech’s cardiovascular portfolio. Wells Fargo analyst Larry Biegelsen expects that the deal will also accelerate its top-line growth.
J&J said on 5 April, it would pay $335 a share in cash for Shockwave and expects to fund the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?